Clinigen Share Discussion Threads

[hutch_pod] 24/7/2014 09:31

Solid growth outside of CTS is encouraging, especially after the H1 revenue shock and lots of cash for expansion too. Pipeline updates on CTS and GAP sound positive. Looks good going forward.

[dasv] 24/7/2014 08:24

encouraging year end update.

[nw99] 24/7/2014 08:08

Good figs no resistance on chart till 450

[montynj] 24/7/2014 01:35

but very low vol

[nermil] 23/7/2014 18:03

Strong move up at end of day. Tipped on upcoming good results maybe? We can't be too far out from some numbers being released. It's plausible.

[cestnous] 22/7/2014 11:04

Strong resistance here. I would expect this to be the bottom. If it breaks down, I will probably think again.

[hutch_pod] 21/7/2014 18:12

Forward PE seems to be around 14 now, though from what I can gather the broker estimates are quite divergent. Will be good to see a new set of 2015 estimates shortly.

Just need the momentum to pick up again surely, fueled by good results and announcements.

[kattatogaru] 21/7/2014 13:18

Can the 4-month slide stop here? We're back where we were in September 2013...What's the forward PE looking like now, anyone got figure? Thx KG

[nw99] 17/7/2014 10:05

Strong buying

[hutch_pod] 16/7/2014 16:30

Thanks Cestnous. Good to know they haven't turned negative.

[hutch_pod] 16/7/2014 12:40

Guess it's batten down the hatches mode.

I've not managed to see either detail of Numis's 650p recommendation or Shares magazine's apparent £24.5m PBT target for 2014. Both sound like pie in the sky at the moment..

[makingmillions] 15/7/2014 11:29

Prefer your option. Here's hoping.

[hutch_pod] 15/7/2014 08:26

Or will we tip-toe past 400..

[makingmillions] 14/7/2014 13:17

From the chart it looks like we could have one more dip down before trading update.

[hutch_pod] 12/7/2014 13:19

Hopefully trading update this month

[kattatogaru] 12/7/2014 12:56

Numis on Friday: Clinigen Group PLC (LON:CLIN)'s stock had its "buy" rating reiterated by Numis Securities Ltd in a research note issued on Friday. They currently have a GBX 650 ($11.15) target price on the stock. Numis Securities Ltd's price target would suggest a potential upside of 70.13% from the company's current price.

It's been a while since we had any real news on this company....

[hutch_pod] 11/7/2014 14:14

Good old Numis. Maintains 650p target.

hxxp://www.mideasttime.com/numis-securities-ltd-reiterates-buy-rating-for-clinigen-group-plc-clin/171258/

[opodio] 10/7/2014 08:39

why is chart showing it at 400p

[nw99] 08/7/2014 07:12

Clinigen upgraded despite target price fallPharmaceutical company Clinigen (CLINC) has been upgraded despite a lowering of the target price to take into account concerns about the clinical trials supply division.Investec analyst Nicholas Keher upgraded the stock from 'hold' to 'buy' and lowered the target price of 560p to 497p after revising earnings per share estimates down for 2015 and 2016. Shares were trading at 389.1p at yesterday's close.'Ahead of the full year 2014 trading statement, which is due in the next few weeks and the preliminary results, we revise our estimates with earnings per share down 3% in 2015 and 7% in 2016,' he said. 'Our new estimates are below consensus in those years, but ahead for 2014.'We think our new estimates have removed much of the risk associated with the clinical trials supply division, which has proven to be volatile. Even against our lower target price, we think the shares offer an attractive opportunity.'

[kattatogaru] 07/7/2014 14:13

Investec has upgraded pharmaceutical group Clinigen from 'hold' to 'buy', saying that even on a lower target price "we think the shares offer an attractive opportunity".

"Clinigen's stock has fallen circa 40% since its interim results in March, when numbers were in line but growth was no longer as 'explosive' as it had been in prior years.

"We now think the shares are too cheap to ignore and, on balance, offer good value for investors."

Investec has cut its target price from 560p to 497p a result of revising its forecasts for the next two years to below consensus to reflect its "more prudent stance" on growth in the Clinical Trial Supply (CTS) division.

CTS revenues are volatile and gross margins different from contract to contract, while currency rate have also moved unfavourably against the company. "Essentially, we think this removes an element of risk that we believe has concerned investors," it said.

Nevertheless, Investec estimates that Clinigen should still grow earnings per share by around 15% per annum over the years ending June 2015 and 2016, "once overhead investment is complete, and as acquired pharmaceutical assets begin to deliver meaningful growth".

What's more, further upside is possible through future acquisitions with the company's cash generation strong.

For the financial year just gone (ended June 30th 2014), the broker still stands above consensus with its estimates.

The shares were 1.2% higher at 389.13p by 12:05 on Monday.

[hutch_pod] 07/7/2014 10:32

From sharecast today

Clinigen: Investec cuts target price from 560p to 497p, while upgrading from hold to buy.

[hydrus] 04/7/2014 23:18

Not sure why £3.50 would be the bottom. Seems like the downward trend will continue until some major positive news.